Login / Register

+44 (0)121 616 3460

+44 (0)121 616 3460


Home

Candidate

Client

About

Jobs

More
Paramount Logo

330 Jobs Now Open
Find Your Perfect Job

Either Select your Country  

Or Use Our Job Search  

Advanced Search

Specialists in the European
Pharmaceutical
Recruitment Sector

Pharmaceutical  Recruitment

Paramount Recruitment is an independent recruitment consultancy based in Birmingham. Established in 2003, the company has gone from strength to strength, and is now a leading recruiter in the healthcare, pharmaceutical, medical device and scientific communities in the UK and Europe.

Click here to find out more about Paramount Recruitment.

9972
followers
& counting...

Follow us on LinkedIn to get the latest updates and news.

Follow Us

Latest News

Picture1

The Growing Role of Pharma in a Genomic Future

10/08/16

Step 1: Diagnosis, Step 2: Treatment – the two cornerstones of clinical practice follow each other naturally, sharing considerations to plan a course of action. But what of initial prevention? What of Step Zero? In their revitalisation of personalised care, supporters of genomic medicine may also change how we utilise preventative measures, and the pharmaceuticals that bring them.

Read More

 
Horizon 20 20

Brexit: The Potential Impact on UK Science

28/07/16

Modern science, perhaps more than any other sphere, benefits from open, interconnected networks of knowledge and of people. We continue to pool larger subject samples, to share more data, and to seek the expertise of specialists across a veritable pick 'n' mix of labs.

Read More

 
100,000 Genome Project

100,000 Genomes – The Future of Diagnosis and Treatment

22/02/16

Until recently, almost 95% of the human genome was neglected by medical research.(1) Despite completing the full genome map in 2003, researchers were sure that only the coding genes – that active 5% – played any role in disease. The full gene sequencing that once took 13 years can now be done in a day, however, and it is only with this leap in technology that the enigmatic 95% has come in to focus.

Read More